The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers

Rajal B. Shah, Yousef Tadros, Brenda Brummell, Ming Zhou

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Immunohistochemical (IHC) staining for ERG is used as a surrogate for TMPRSS2-ERG gene fusion, a specific molecular event seen in ∼50% of prostate carcinomas (PCas) and ∼20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions. We studied 84 "atypical glands suspicious for cancer (ATYP)" cases using multiplex ERG/α-methylacyl-CoA-racemase (AMACR)/high- molecular-weight cytokeratin/p63 IHC to determine how often ERG contributes to resolving an ATYP diagnosis beyond that provided by AMACR and basal markers. Final diagnoses of benign, ATYP, and cancer were rendered after review of morphology and all markers in 3, 30, and 51 cases, respectively. Of 51 cancer diagnoses, 45% and 94% were positive for ERG and AMACR, respectively. Of 30 atypical diagnoses, 10% and 67% were positive for ERG and AMACR, respectively. Of 3 benign diagnoses, none and 83% were positive for ERG and AMACR, respectively. Three ERG-positive atypical cases were classified as "HGPIN with adjacent ATYP." ERG was expressed in adjacent noncancer glands of 20% of PCas, whereas AMACR was expressed in noncancer glands in all diagnostic categories in 40% of cases. Positive ERG staining helped establish the initial ATYP diagnosis to PCa in 28% cases whose diagnoses would otherwise remain ATYP based on AMACR and basal markers. ERG positivity in small atypical glands where HGPIN diagnosis is excluded helps establish a definitive cancer diagnosis in a small proportion of additional ATYP cases. We recommend judicious use of ERG, preferably as a component of multiplex IHC, in evaluation of difficult prostate biopsies.

Original languageEnglish (US)
Pages (from-to)786-794
Number of pages9
JournalHuman Pathology
Volume44
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Racemases and Epimerases
Coenzyme A
Prostate
Biopsy
Prostatic Intraepithelial Neoplasia
Neoplasms
Gene Fusion
Staining and Labeling
Carcinoma
Keratins
Molecular Weight

Keywords

  • α-Methylacyl-CoA-racemase (AMACR)
  • ERG
  • High-molecular-weight cytokeratin (HMWCK)
  • p63
  • Prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers. / Shah, Rajal B.; Tadros, Yousef; Brummell, Brenda; Zhou, Ming.

In: Human Pathology, Vol. 44, No. 5, 01.05.2013, p. 786-794.

Research output: Contribution to journalArticle

@article{959734aec92f4a4dba9ef97a75187a98,
title = "The diagnostic use of ERG in resolving an {"}atypical glands suspicious for cancer{"} diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers",
abstract = "Immunohistochemical (IHC) staining for ERG is used as a surrogate for TMPRSS2-ERG gene fusion, a specific molecular event seen in ∼50{\%} of prostate carcinomas (PCas) and ∼20{\%} of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions. We studied 84 {"}atypical glands suspicious for cancer (ATYP){"} cases using multiplex ERG/α-methylacyl-CoA-racemase (AMACR)/high- molecular-weight cytokeratin/p63 IHC to determine how often ERG contributes to resolving an ATYP diagnosis beyond that provided by AMACR and basal markers. Final diagnoses of benign, ATYP, and cancer were rendered after review of morphology and all markers in 3, 30, and 51 cases, respectively. Of 51 cancer diagnoses, 45{\%} and 94{\%} were positive for ERG and AMACR, respectively. Of 30 atypical diagnoses, 10{\%} and 67{\%} were positive for ERG and AMACR, respectively. Of 3 benign diagnoses, none and 83{\%} were positive for ERG and AMACR, respectively. Three ERG-positive atypical cases were classified as {"}HGPIN with adjacent ATYP.{"} ERG was expressed in adjacent noncancer glands of 20{\%} of PCas, whereas AMACR was expressed in noncancer glands in all diagnostic categories in 40{\%} of cases. Positive ERG staining helped establish the initial ATYP diagnosis to PCa in 28{\%} cases whose diagnoses would otherwise remain ATYP based on AMACR and basal markers. ERG positivity in small atypical glands where HGPIN diagnosis is excluded helps establish a definitive cancer diagnosis in a small proportion of additional ATYP cases. We recommend judicious use of ERG, preferably as a component of multiplex IHC, in evaluation of difficult prostate biopsies.",
keywords = "α-Methylacyl-CoA-racemase (AMACR), ERG, High-molecular-weight cytokeratin (HMWCK), p63, Prostate cancer",
author = "Shah, {Rajal B.} and Yousef Tadros and Brenda Brummell and Ming Zhou",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.humpath.2012.06.024",
language = "English (US)",
volume = "44",
pages = "786--794",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers

AU - Shah, Rajal B.

AU - Tadros, Yousef

AU - Brummell, Brenda

AU - Zhou, Ming

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Immunohistochemical (IHC) staining for ERG is used as a surrogate for TMPRSS2-ERG gene fusion, a specific molecular event seen in ∼50% of prostate carcinomas (PCas) and ∼20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions. We studied 84 "atypical glands suspicious for cancer (ATYP)" cases using multiplex ERG/α-methylacyl-CoA-racemase (AMACR)/high- molecular-weight cytokeratin/p63 IHC to determine how often ERG contributes to resolving an ATYP diagnosis beyond that provided by AMACR and basal markers. Final diagnoses of benign, ATYP, and cancer were rendered after review of morphology and all markers in 3, 30, and 51 cases, respectively. Of 51 cancer diagnoses, 45% and 94% were positive for ERG and AMACR, respectively. Of 30 atypical diagnoses, 10% and 67% were positive for ERG and AMACR, respectively. Of 3 benign diagnoses, none and 83% were positive for ERG and AMACR, respectively. Three ERG-positive atypical cases were classified as "HGPIN with adjacent ATYP." ERG was expressed in adjacent noncancer glands of 20% of PCas, whereas AMACR was expressed in noncancer glands in all diagnostic categories in 40% of cases. Positive ERG staining helped establish the initial ATYP diagnosis to PCa in 28% cases whose diagnoses would otherwise remain ATYP based on AMACR and basal markers. ERG positivity in small atypical glands where HGPIN diagnosis is excluded helps establish a definitive cancer diagnosis in a small proportion of additional ATYP cases. We recommend judicious use of ERG, preferably as a component of multiplex IHC, in evaluation of difficult prostate biopsies.

AB - Immunohistochemical (IHC) staining for ERG is used as a surrogate for TMPRSS2-ERG gene fusion, a specific molecular event seen in ∼50% of prostate carcinomas (PCas) and ∼20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions. We studied 84 "atypical glands suspicious for cancer (ATYP)" cases using multiplex ERG/α-methylacyl-CoA-racemase (AMACR)/high- molecular-weight cytokeratin/p63 IHC to determine how often ERG contributes to resolving an ATYP diagnosis beyond that provided by AMACR and basal markers. Final diagnoses of benign, ATYP, and cancer were rendered after review of morphology and all markers in 3, 30, and 51 cases, respectively. Of 51 cancer diagnoses, 45% and 94% were positive for ERG and AMACR, respectively. Of 30 atypical diagnoses, 10% and 67% were positive for ERG and AMACR, respectively. Of 3 benign diagnoses, none and 83% were positive for ERG and AMACR, respectively. Three ERG-positive atypical cases were classified as "HGPIN with adjacent ATYP." ERG was expressed in adjacent noncancer glands of 20% of PCas, whereas AMACR was expressed in noncancer glands in all diagnostic categories in 40% of cases. Positive ERG staining helped establish the initial ATYP diagnosis to PCa in 28% cases whose diagnoses would otherwise remain ATYP based on AMACR and basal markers. ERG positivity in small atypical glands where HGPIN diagnosis is excluded helps establish a definitive cancer diagnosis in a small proportion of additional ATYP cases. We recommend judicious use of ERG, preferably as a component of multiplex IHC, in evaluation of difficult prostate biopsies.

KW - α-Methylacyl-CoA-racemase (AMACR)

KW - ERG

KW - High-molecular-weight cytokeratin (HMWCK)

KW - p63

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84876466414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876466414&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.06.024

DO - 10.1016/j.humpath.2012.06.024

M3 - Article

VL - 44

SP - 786

EP - 794

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 5

ER -